Studies on liposomal delivery of dopamine to brain via nasal route

Abstract

Drug delivery to brain remains the major challenge for treatment of central nervous system newline(CNS) disorders due to formidable mechanisms protecting the brain from unwanted substances newlinefrom main circulation system. The emerging loom is to bypass blood brain barrier (BBB) by newlineusing a novel, practical, simple and non invasive approach such as intranasal delivery. This route newlineis already investigated to found to bypass BBB and target CNS in treatment of various newlineneurological disorders. The strategy of applying drugs encapsulated into nanocarriers (polymeric newlineand lipid based) to the olfactory epithelium could potentially improve the efficacy and direct CNS newlinedelivery of drugs. The aim of this work is to deliver Dopamine directly to brain via nasal newlineapplication using liposomal drug carriers to improve selective biodistribution to brain and its newlinetherapeutic efficacy to suggest future prospective that may benefit in progressive treatment for newlineneurodegenerative disorders. To achieve this broad objective, following studies were carried out newlinein this research work. newlineAppropriate analytical and bioanalytical methods based on spectrophotometric and liquid newlinechromatography were developed and validated for estimating Dopamine HCl. The developed newlinemethods were simple, selective, sensitive, accurate and precise in the determination of Dopamine newlineHCl. The analytical method was applied to determine Dopamine in liposomes and in the in-vitro newlinedissolution sample and the bioanalytical method was used to estimate Dopamine in plasma, brain, newlinenasal fluid, lungs, trachea and oesophagus samples in pharmacokinetic and biodistribution newlinestudies. Prior to the formulation development, preformulation studies were performed to newlineestablish necessary physicochemical data of the drug. Studies were performed to concentrate on newlineproduct specific questions related to drug-excipient compatibility, stability etc. The drug-excipient newlinecompatibility studies indicated no physical or chemical changes at ambient and accelerated newlinestorage conditions. Thus, drug-excipient compatibility studies.